Medical - Diagnostics & Research industry analysis: EL7 Score and the best stocks ranked by value, profitability, and momentum.
99 of 151
P/E 32.3 vs period average 29.6 Richer than its history
Ranked among 29 stocks with a market cap above $500M. Smaller companies are excluded from the ranking.
Rank | Company | Price | P/E | Value | Growth | Quality | EL7 Score |
|---|---|---|---|---|---|---|---|
| 1/29 | ![]() | $50.26 | 24.3 | 73 | 76 | 89 | 100 |
| 2/29 | ![]() | $40.87 | 29.2 | 74 | 89 | 92 | 98 |
| 3/29 | ![]() | $235.02 | 24.9 | 91 | 47 | 77 | 94 |
| 4/29 | ![]() | $311.54 | 25.7 | 95 | 65 | 55 | 91 |
| 5/29 | ![]() | $504.70 | 35.4 | 38 | 58 | 95 | 79 |
| 6/29 | ![]() | $587.52 | 34.2 | 42 | 61 | 91 | 77 |
| 7/29 | ![]() | $1293.52 | 29.1 | 61 | 26 | 86 | 74 |
| 8/29 | ![]() | $98.77 | 139.8 | 12 | 98 | 63 | 73 |
| 9/29 | ![]() | $206.45 | 38.4 | 32 | 20 | 98 | 71 |
| 10/29 | ![]() | $261.77 | 32.3 | 89 | 41 | 69 | 70 |
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Insider purchases in the sector's stocks
Funds that track the sector and each fund's exposure to it.
Fund | Exposure | Assets | Expense |
|---|---|---|---|
| IBBiShares Biotechnology ETF | 100.0% | $10B | 0.44% |
| VHTVanguard Health Care ETF | 100.0% | $21B | 0.09% |
| IHIiShares U.S. Medical Devices ETF | 99.7% | $3B | 0.37% |
| XLVState Street Health Care Select Sector SPDR ETF | 99.2% | $43B | 0.08% |
The percentage is the sector's share of the fund's assets, per the latest available data.
Upgrades and downgrades on the sector's stocks